News About: Pharm. Affairs
Evolution of domestic botulinum by Nabota, Botulax and Innotox
Development of domestically-developed botulinum toxin products has drawn attention. As amazingly securing 10 indications, they have challenged to the stronghold of Allergan’s Botox that is sold in 75 different countri...
Foreign expansion of hypertension/hyperlipidemia complexes
Domestic hypertension and hyperlipidemia complexes have aggressively knocked on the door of foreign markets. They have either been directly conducted on foreign clinical trials or been jointly developed with global bi...
LAMA+LABA complex, ‘Vahelva Respimat’ launches with insurance benefit on April
A new LAMA+LABA complex drug, Vahelva Respimat(generic name: tiotropium+olodaterol) is expected to be launched on April 1.
On the 8th, Boehringer Ingelheim(CEO Gi-hwan Park) introduced Vahelva Respimat and Spiriva R...
Life Prolongation Decision Act will decrease anticancer market?
If the ‘Act on the Decision for Life Prolongation for Patients on Hospice, Palliative Care and Dying(Life Prolongation Decision Act)’ officially announced last February is enforced, will anticancer prescriptions decre...
Generics poured out before ‘ezetimibe’ patent expiration of KRW 60 billion
Facing the patent expiration of the ezetimibe drug(product name: Ezetrol), a hyperlipidemia treatment, a number of ezetimibe+statin complexes emerged and foretold fierce competition.
The substance patent expiration o...
Over NIP, MSD and GSK requests for double and single prices respectively
While negotiations for cervical cancer vaccines have started among the Korea Center for Disease Control and Prevention(KCDC), MSD and GSK, the two companies were observed to hope double price and single price respecti...
KRW 100 billion Viread market preoccupied by Chong Kun Dang
Chong Kun Dang has took a step forward for commercialization of an incrementally modified drug of Viread(generic name: tenofovir), a chronic hepatitis B treatment.
The Ministry of Food and Drug Safety(MFDS) approved...
Novartis loses against Dongkook Pharmaceutical over hyperpituitarism patent
Novartis lost on a trail for injunction against infringement of the hyperpituitarism patent against Dongkook Pharmaceutical.
The 11th Civil Affairs Division, Seoul Central District Court, dismissed the request for in...
Janssen’s HIV treatment, ‘Presecobics’ applied by health insurance from March
Janssen Korea(CEO Ok-yeon Kim) announced ‘Presecobics(generic name: darunavir 800mg, cobicistat 150mg),’ a complex human immunodeficiency virus(HIV) treatment, will be applied by the National Health Insurance from the...
Original products’ claims have enlarged after the drug price cuts
The drug price cuts on April 2012 was enforced with changes that are important in the drug pricing system.
It had had contained abolition of the stepped drug pricing system which set drug prices depending on generic...
